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We report three novel CFTR missense mutations detected in Spanish patients from Galicia (North West of Spain). In the first case, a patient
homozygous for a novel S1045Y mutation died due to pulmonary problems. In the other two cases, both heterozygous for novel mutations
combined with the F508del mutation, clinical symptoms were different depending on the mutation, detected as M595I and A107V.
© 2008 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Galicia; Spain; CFTR; Mutation; Cystic fibrosis1. Introduction
More than 1400 different mutations within the CFTR gene
have been described to date [1]. It is known that there are
mutations associated with severe cystic fibrosis (CF) phenotype
and mutations associated with milder or atypical CF disease. The
potential of a mutation to contribute to the phenotype depends on
its type, localization in the gene and interactions with secondary
modifying factors [2,3]. It is assumed that nonsense, frameshift
and splice site mutations result in the loss of functional CFTR.
Missense mutations are more problematical in that they may only
partially affect CFTR function. As the amount of functioning
CFTR appears to be related to clinical status, somemutations with
more modest effect may present congenital absence of the vas
deferens with or without mild respiratory disease.
From 2004, when we started sequencing the exonic regions of
the CFTR gene in our laboratory, we have sequenced nearly 150
samples of patients from Galicia (North West of Spain) with
possible or independently diagnosed cystic fibrosis. From these⁎ Corresponding author. Fundacion Publica Galega de Medicina Xenomica.
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doi:10.1016/j.jcf.2008.05.009analyses we discovered three mutations in the CFTR gene not
previously described in the literature: one homozygous S1045Y
and two compound heterozygous, A107V and M595I, both
combined with the F508del mutation. Each of these is a new
missense mutation located in exons 17A, 4 and 13, respectively
(Table 1). No other accompanying mutations were identified after
complete sequencing of the CFTR gene in each case.
2. Materials and methods
Genomic DNA was extracted from anticoagulated blood
using the Wizard Genomic DNA purification kit (Promega).
The sequencing reaction was performed using the Big Dye
terminator v3.1 cycle sequencing kit (Applied Biosystems)
and analyzed on an ABI 3730XL Genetic Analyzer (Applied
Biosystems).
3. Case reports
3.1. Case 1: patient homozygous for mutation S1045Y
A female born in 1972, nulliparous, diagnosed with allergic
bronchial asthma at her local primary healthcare centre with
allergic sensibility to dust mites, gramineous pollen andd by Elsevier B.V. All rights reserved.
Table 1
New CFTR mutations found in Galician patients and bioinformatic predictions
AA change Exon Polyphen a PSIC b PMUTc Reliability d
S1045Y 17A Possibly damaging 1.864 Pathological 7
M595I 13 Benign 1.310 Neutral 3
A107V 4 Possibly damaging 1.602 Pathological 2
a Polyphen prediction about the impact of the amino acid substitution on the
function of the protein.
b Polyphen value which correlates with the probability of one missense
mutation to be pathogenic. Large differences in PSIC score (above 1.5) may
indicate that the substitution of interest is rarely or never observed in the protein
family.
c PMUT prediction about the pathological character of the mutation.
d PMUT index which values vary between 0 and 9. Low values correspond to
poorer predictions and higher values to better predictions.
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2001 the patient was diagnosed with bronchopulmonar
allergenic aspergillosis.
In 2005 she was hospitalized due to a deterioration of her
respiratory symptoms and suggestive data of cystic fibrosis:
dyspnoea, productive cough, nasal congestion, diffuse bronch-
iectasis with central predominance and elevated sweat tests
(N90 mEq/L). In the familial study it was found that her only
siblings (two brothers) had both died, one of them with biliary
pathology and the other with cardiac pathology. In the blood
analysis there was leucocytosis (11,300 cel/mm3), eosinophilia
(8.3%) and a total IgE of 1508 ku/L to Aspergillus. In the
sputum culture Candida albicans was isolated while spiro-
metric tests showed levels: FVC (Forced Vital Capacity) 67%,
FEV1 (Forced Expiratory Volume) 53%, FEV1/FVC 78%.
From that year the patient suffered many hospitalizations due
to respiratory infections with Pseudomona aeruginosa, receiv-
ing several cycles of antibiotic treatments and tobramicin
inhalation over extended periods. At that moment the possibility
of a lung transplant was suggested because of the deteriorating
respiratory condition.
In April of 2007 and after many urgent hospitalizations
because of worsening breathing symptoms (oxygen saturation
88% with a Ventimask at 100%) the patient was admitted to
intensive care, was intubated and connected to a mechanical
ventilatory system receiving treatment with antibiotics. After a
brief initial improvement the patient suffered a fresh deterioration
with leucocytosis and raised fever. P. aeruginosa andMorganella
morganii were isolated from cultures.
After the patient stabilized, she was moved to a transplantation
unit where copious and thick mucous secretions were found in
bronchoscopy throughout the bronchial tree, especially in the
upper lobe. At the same time the secretions were cleaned and
cultured, showing the presence of P. aeruginosa with mucoid
morphotype. Twelve days later the patient presented an oliguric
renal failure and began a progressive respiratory and haemody-
namic deterioration resulting in refractory shock and death three
days after.
In this patient we found amino acid change S1045Y: serine
(TCT) to tyrosine (TAT) at codon 1045 in exon 17A of CFTR.
Interestingly, there are no mutations described in this codon to
date.Further familial studies showed that both parents had the
same mutation in heterozygous form and that there was parental
consanguinity (first cousins).
3.2. Case 2: patient M595I/F508del
A male born in 1991, the first live birth (two previous
stillbirths) with no neonatal pathology. From the first year of life
he suffered frequent catarrhs with dry cough at night and distress.
He was diagnosed with allergenic rhinitis and bronchial asthma
with sensitivity to domestic dust mites in 1999. In a routine
consultation the patient showed a sweat testwith elevated chloride
levels, so was referred to a cystic fibrosis unit.
In 2007 radiology failed to show any pulmonary lesions or
gastroenterologic pathology, but chloride levels were still very
elevated (N100 mEq/L) while spirometry was also normal. The
clinical evolution was practically asymptomatic, showing only
bronchial asthma episodes. The age of the patient precluded the
ascertainment of the sterility status.
In this patient we found amino acid change M595I:
methionine (ATG) to isoleucine (ATA) at codon 595 in exon
13 of CFTR. A previously reported mutation [4] described at the
same codon resulted in a change from methionine to threonine.
The patient we describe was found to have a F508del mutation
in combination with M595I.
3.3. Case 3: patient A107V/F508del
A male born in 1981, diagnosed with clinical symptoms
compatible with cystic fibrosis at 8 years old, with a F508del
mutation detected at that stage. The patient showed a serious
respiratory condition with the following spirometric data: FVC:
40%, FEV1: 27%, FEV1/FVC: 55%.
In 1993 he required hospitalization for a thoracic drainage due
to a pneumothorax. In 2005 he presented a haemoptysis with
embolyzation where Staphylococcus maltophilia and Staphylo-
coccus aureus were cultured. In 2007 he was hospitalized again
with an important haemoptysis (350 cc approx.) without any other
symptoms. Blood analysis showed leucocytosis, microcitic
hypochromic anaemia and acute respiratory insufficiency. Thorax
radiography gave bilateral brochiectasis with central and left
predominance. In the sputum culture C. albicans and S. aureus
were isolated. The haemoptysis was self limited and probably
related to a bronchial sepsis. The sweat test showed chloride
levels of 96 mEq/L. The patients required substitutive enzymatic
treatment with pancreatic enzymes.
In this patient we found an amino acid change A107V from
alanine (GCT) to valine (GTT) at codon 107 in exon 4 of the
CFTR. A mutation recently described in the same codon
resulted in a change from alanine to glycine in a patient with
asthenospermia [5].
4. Discussion
We identified three novel missense mutations that led to
different amino acid changes in the CFTR protein and to different
clinical symptoms in the patients. To predict the possible impact
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protein, we used the bioinformatic tools PolyPhen [6] and Pmut
[7] which take into account structural and evolutionary properties
to characterize a substitution [8,9].
The patient homozygous for mutation S1045Y resulted in an
amino acid change from serine to tyrosine that appeared to be the
cause of a serious cystic fibrosis condition with multiorganic
repercussions and fatal consequences for the patient. PolyPhen and
Pmut predicted a possibly damaging or pathological repercussion,
respectively, for this mutation. The vast majority of mutations are
at frequencies under 0.1%or represent privatemutations, normally
with a background of the F508del major mutation. So, in the
simple cystic fibrosis heterozygotes, any effect of the rare point
mutations on the products of the normal CFTR gene cannot be
estimated directly due to the co-function of the trans normal CFTR
gene. Therefore rare cases of homozygosity, related in the
described case to consanguinity, can help to understand the effect
of the respective mutations on CFTR gene function.
The patient with genotypeM595I/F508del did not show severe
respiratory symptoms. In fact, with appropriate follow up, the
patient seemed to be practically asymptomatic. The substitution
of methionine for isoleucine in amino acid 595 appeared to show
mild clinical effects. In this case the prediction of PolyPhen and
Pmut programs gave a perfect correlation with the clinical status
of the patient, predicting the mutation to be benign and neutral,
respectively.
In the last case, a patient with the A107V/F508del genotype
showed important pulmonary problems. The alanine to valine
substitution of amino acid 107 appeared to give more serious
repercussions in the clinical evolution of the patient. Predictions
of the programs were once again in accordance with the
symptoms: PolyPhen predicted possibly damaging effects and
Pmut pathological effects.
These three cases clearly reflect a common problem in the
genetic counselling of cystic fibrosis, specifically that the
spectrum of mutations in the CFTR gene gives rise to a highly
variable clinical phenotype that may not be predictable from the
genotype. In these cases bioinformatics tools can help guide
advice given to the patient, but even with such predictions it is
impossible to have certainty of the clinical evolution of the
condition. In our study we detected three patients each with
novel mutations and indicating different clinical evolution,
ranging from a patient that was nearly asymptomatic to a patient
who died because of the illness.
We also note that these patients would not have been
genetically identified using the current recommended panel for
CFTR genetic analysis, particularly the panel based on the
American College of Medical Genetics guidelines [10]. This
panel is used as a standard in many countries and used as the core
mutation set to develop different commercial kits. After severalyears of experience in our laboratory, we have realized the
importance of sequencing the whole CFTR gene, especially
having identified an allele with a mutation (generally included in
commercial kits). It is not unusual to encounter mutations that are
not included in commercial kits and we have experienced this
situation on several other occasions in addition to the cases
described here.
Finally, case 1 illustrates the importance of an early genetic
analysis for patients with suspicion of cystic fibrosis. The patient,
homozygous for mutation S1045Y, probably would have been
benefit from an early antibiotic treatment avoiding the severe lung
problems that finally developed. An early genetic analysis can be
useful even for patients showing no clear symptoms of cystic
fibrosis in order to avoid this events. Furthermore, the case
illustrates the limitations inherent in the use ofmutation panels for
CF neonatal screening and the necessity of complete CFTR gene
analysis or more complete mutation panels. In Galicia we are
developing a neonatal screening program based in a panel with all
CFTR mutations previously detected in our population, assisted
by complete CFTR gene analysis when clinical data indicate
suspicion of CF.
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